Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BOEHRINGER INGELHEIM VIRAMUNE FOR COMBINATION USE WILL BE ON THE MARKET BY END OF JULY; INTERACTION STUDIES WITH PROTEASE INHIBITORS PART OF PHASE IV

Executive Summary

Boehringer Ingelheim plans to launch Viramune (nevirapine) by late July, the company said following FDA's June 21 accelerated approval of the HIV treatment.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel